The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)

Henry Krum

Centre of Cardiovascular Research & Education in Therapeutics

Department of Epidemiology & Preventive Medicine

Monash University/Alfred Hospital

Melbourne VIC 3004



Name/email consistency: high



  • Centre of Cardiovascular Research & Education in Therapeutics, Department of Epidemiology & Preventive Medicine, Monash University/Alfred Hospital, Melbourne VIC 3004, Australia. 2004 - 2011
  • Monash University/Alfred Hospital, Melbourne, Victoria 3004, Australia. 2010
  • Department of Epidemiology and Preventive Medicine, NHMRC Centre of Clinical Research Excellence in Therapeutics, Monash University, Alfred Hospital, Australia. 1999 - 2009
  • Monash University, Melbourne, Australia. 2006
  • Clinical Pharmacology Unit, Monash University, Alfred Hospital, Melbourne, VIC. 1998 - 2002
  • Alfred Healthcare Group, Prahran, VIC. 1997


  1. Direct renin inhibition in addition to or as an alternative to angiotensin converting enzyme inhibition in patients with chronic systolic heart failure: rationale and design of the Aliskiren Trial to Minimize OutcomeS in Patients with HEart failuRE (ATMOSPHERE) study. Krum, H., Massie, B., Abraham, W.T., Dickstein, K., Kober, L., McMurray, J.J., Desai, A., Gimpelewicz, C., Kandra, A., Reimund, B., Rattunde, H., Armbrecht, J. Eur. J. Heart Fail. (2011) [Pubmed]
  2. Renin inhibitors in chronic heart failure: the Aliskiren Observation of Heart Failure Treatment study in context. Krum, H., Maggioni, A. Clin. Cardiol (2010) [Pubmed]
  3. Baseline characteristics of the Nateglinide and Valsartan Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) trial population: comparison with other diabetes prevention trials. Krum, H., McMurray, J.J., Horton, E., Gerlock, T., Holzhauer, B., Zuurman, L., Haffner, S.M., Bethel, M.A., Holman, R.R., Califf, R.M. Cardiovasc. Ther (2010) [Pubmed]
  4. Baseline factors associated with congestive heart failure in patients receiving etoricoxib or diclofenac: multivariate analysis of the MEDAL program. Krum, H., Curtis, S.P., Kaur, A., Wang, H., Smugar, S.S., Weir, M.R., Laine, L., Brater, D.C., Cannon, C.P. Eur. J. Heart Fail. (2009) [Pubmed]
  5. Factors associated with blood pressure changes in patients receiving diclofenac or etoricoxib: results from the MEDAL study. Krum, H., Swergold, G., Curtis, S.P., Kaur, A., Wang, H., Smugar, S.S., Weir, M.R., Laine, L., Brater, D.C., Cannon, C.P. J. Hypertens. (2009) [Pubmed]
  6. Consider beta blockers for patients with heart failure. Krum, H. BMJ (2009) [Pubmed]
  7. Beta-blockers should remain as first-line therapy in the management of hypertension. Krum, H. Int. J. Clin. Pract. (2008) [Pubmed]
  8. Novel therapies blocking the renin-angiotensin-aldosterone system in the management of hypertension and related disorders. Krum, H., Gilbert, R.E. J. Hypertens. (2007) [Pubmed]
  9. Impact of statin therapy on clinical outcomes in chronic heart failure patients according to beta-blocker use: results of CIBIS II. Krum, H., Bailey, M., Meyer, W., Verkenne, P., Dargie, H., Lechat, P., Anker, S. Cardiology (2007) [Pubmed]
  10. Statins and symptomatic chronic systolic heart failure: a post-hoc analysis of 5010 patients enrolled in Val-HeFT. Krum, H., Latini, R., Maggioni, A.P., Anand, I., Masson, S., Carretta, E., Ingrillì, F., Pettinati, G., Glazer, R., Tognoni, G., Cohn, J. Int. J. Cardiol. (2007) [Pubmed]
  11. Therapeutic potential of blockade of the urotensin II system in systemic hypertension. Krum, H., Kemp, W. Curr. Hypertens. Rep. (2007) [Pubmed]
  12. Tolerability of beta-blockers in elderly patients with chronic heart failure: the COLA II study. Krum, H., Hill, J., Fruhwald, F., Sharpe, C., Abraham, G., Zhu, J.R., Poy, C., Kragten, J.A. Eur. J. Heart Fail. (2006) [Pubmed]
  13. Effect of angiotensin II receptor blockade on autonomic nervous system function in patients with essential hypertension. Krum, H., Lambert, E., Windebank, E., Campbell, D.J., Esler, M. Am. J. Physiol. Heart Circ. Physiol. (2006) [Pubmed]
  14. Are beta-blockers needed in patients receiving spironolactone for severe chronic heart failure? An analysis of the COPERNICUS study. Krum, H., Mohacsi, P., Katus, H.A., Tendera, M., Rouleau, J.L., Fowler, M.B., Coats, A.J., Roecker, E.B., Packer, M. Am. Heart J. (2006) [Pubmed]
  15. Blood pressure effects of COX-2 inhibitors. Krum, H., Aw, T.J., Liew, D., Haas, S. J. Cardiovasc. Pharmacol. (2006) [Pubmed]
  16. Does the presence of heart failure alter prescribing of drug therapy after myocardial infarction? A multicentre study. Krum, H., Meehan, A., Varigos, J., Loane, P.R., Billah, B. Med. J. Aust. (2006) [Pubmed]
  17. Prognostic benefit of beta-blockers in patients not receiving ACE-Inhibitors. Krum, H., Haas, S.J., Eichhorn, E., Ghali, J., Gilbert, E., Lechat, P., Packer, M., Roecker, E., Verkenne, P., Wedel, H., Wikstrand, J. Eur. Heart J. (2005) [Pubmed]
  18. Could risk stratification aid the treatment of patients with acute decompensated heart failure?. Krum, H. Nature Clinical Practice. Cardiovascular Medicine (2005) [Pubmed]
  19. A feeling in the waters: diagnosis of heart failure using urinary natriuretic peptides. Krum, H., Liew, D. Clin. Sci. (2004) [Pubmed]
  20. Bush telegraph. Improving outcomes for rural and remote patients with chronic heart failure. Krum, H., Tonkin, A., Piterman, L. Aust. Fam. Physician (2004) [Pubmed]
  21. Tolerability of carvedilol in heart failure: clinical trials experience. Krum, H. Am. J. Cardiol. (2004) [Pubmed]
  22. Cardiovascular effects of selective cyclooxygenase-2 inhibitors. Krum, H., Liew, D., Aw, J., Haas, S. Expert. Rev. Cardiovasc. Ther (2004) [Pubmed]
  23. Eplerenone in the treatment of chronic heart failure. Krum, H., Liew, D. Expert. Rev. Cardiovasc. Ther (2004) [Pubmed]
  24. Effects of initiating carvedilol in patients with severe chronic heart failure: results from the COPERNICUS Study. Krum, H., Roecker, E.B., Mohacsi, P., Rouleau, J.L., Tendera, M., Coats, A.J., Katus, H.A., Fowler, M.B., Packer, M. JAMA (2003) [Pubmed]
  25. Recent advances in the management of chronic heart failure. Krum, H., Liew, D. Aust. Fam. Physician (2003) [Pubmed]
  26. Beta-blockers in chronic heart failure: what have we learned? What do we still need to know?. Krum, H. Curr. Opin. Pharmacol (2003) [Pubmed]
  27. New developments in the pharmacological treatment of chronic heart failure. Krum, H., Liew, D. Expert. Opin. Investig. Drugs (2003) [Pubmed]
  28. Current status of endothelin blockade for the treatment of cardiovascular and pulmonary vascular disease. Krum, H., Liew, D. Curr. Opin. Investig. Drugs (2003) [Pubmed]
  29. Demographics and concomitant disorders in heart failure. Krum, H., Gilbert, R.E. Lancet (2003) [Pubmed]
  30. Comparative metabolic effects of hydrochlorothiazide and indapamide in hypertensive diabetic patients receiving ACE inhibitor therapy. Krum, H., Skiba, M., Gilbert, R.E. Diabet. Med. (2003) [Pubmed]
  31. New and emerging drug therapies for the management of acute heart failure. Krum, H., Liew, D. Intern. Med. J (2003) [Pubmed]
  32. Statins and chronic heart failure: do we need a large-scale outcome trial?. Krum, H., McMurray, J.J. J. Am. Coll. Cardiol. (2002) [Pubmed]
  33. Efficacy of eplerenone added to renin-angiotensin blockade in hypertensive patients. Krum, H., Nolly, H., Workman, D., He, W., Roniker, B., Krause, S., Fakouhi, K. Hypertension (2002) [Pubmed]
  34. Guidelines for management of patients with chronic heart failure in Australia. Krum, H. Med. J. Aust. (2001) [Pubmed]
  35. Diagnostic and therapeutic potential of the endothelin system in patients with chronic heart failure. Krum, H., Denver, R., Tzanidis, A., Martin, P. Heart. Fail. Rev (2001) [Pubmed]
  36. Differentiation in the angiotensin II receptor 1 blocker class on autonomic function. Krum, H. Curr. Hypertens. Rep. (2001) [Pubmed]
  37. New and emerging pharmacological strategies in the management of chronic heart failure. Krum, H. Curr. Opin. Pharmacol (2001) [Pubmed]
  38. Recent advances in the management of chronic heart failure. Krum, H. Aust. N. Z. J. Med (2000) [Pubmed]
  39. Beta-blockers in heart failure. The 'new wave' of clinical trials. Krum, H. Drugs (1999) [Pubmed]
  40. New drugs, old drugs. Beta-adrenoceptor blocking agents. Krum, H., Pillay, P. Med. J. Aust. (1998) [Pubmed]
  41. New and emerging drug treatments for hypertension. Krum, H., Pellizzer, A.M. Aust. Fam. Physician (1998) [Pubmed]
  42. Inhibitors of the renin-angiotensin system. Krum, H. Med. J. Aust. (1997) [Pubmed]
WikiGenes - Universities